Intel heads into its April 23 earnings with rising investor expectations , but the key question remains whether AI-driven CPU demand can offset ongoing margin weakness . Revenue Stable, But Margins Under Pressure Intel is expected to deliver Q1 revenue around US$12.4 billion , slightly above the midpoint of its guidance range. However, the real concern lies in profitability: Gross margin guided at 34.5% , down from 39.2% a year ago EPS near breakeven (~US$0.00) vs US$0.13 last year This highlights continued pressure from costs, utilisation, and product mix , despite improving demand signals. AI CPUs: A Key Growth Driver Intel’s near-term bullish case centers on AI-related CPU demand , particularly its Xeon processors. A key development is its partnership with Alphabet , which reinforces: Intel’s role in AI data centre infrastructure Growing demand for AI inference and general-purpose computing Investors will watch c...
Swiss pharmaceutical giant Novartis announced plans to wind up operations at MorphoSys sites in Munich, Germany, and Boston, USA, by the end of 2025, affecting approximately 330 jobs.
Key Details
Acquisition Context:
- Novartis acquired MorphoSys earlier this year and is restructuring as part of an evaluation of its R&D setup.
Impact on Employees:
- Affected employees, approximately 330 roles, were notified in mid-November.
- Novartis has committed to supporting impacted individuals through the transition.
Official Statement:
- "We have communicated our intention to exit the MorphoSys sites by end of 2025," said a Novartis spokesperson in a statement to Reuters.
- The decision reflects Novartis' evolving research and development priorities.
Comments
Post a Comment